Double-responsive hyaluronic acid-based prodrugs for efficient tumour targeting.
Mater Sci Eng C Mater Biol Appl
; 131: 112475, 2021 Dec.
Article
em En
| MEDLINE
| ID: mdl-34857264
ABSTRACT
Hyaluronic acid (HA)-based prodrugs bearing double-responsive (acid pH or oxidation) boronates of catechol-containing drugs were used to treat xenografted human prostate tumours (LNCaP) in SCID mice. The HA prodrugs accumulated significantly only in tumours (impressively, up to 40% of the injected dose after 24 h) and in liver, with negligible - actually anti-inflammatory - consequences in the latter. A quercetin-HA prodrug significantly slowed down tumour growth, in a dose-dependent fashion and with a much higher efficacy (up to 4 times) than equivalent doses of free quercetin. In short, boronated HA appears to be a very promising platform for targeted chemotherapy.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
/
Tipos_de_cancer
/
Outros_tipos
Base de dados:
MEDLINE
Assunto principal:
Pró-Fármacos
/
Neoplasias
Limite:
Animals
Idioma:
En
Revista:
Mater Sci Eng C Mater Biol Appl
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Itália